Ozempic maker Novo Nordisk to cut 11% of workforce

Core Viewpoint - Novo Nordisk is implementing a significant global restructuring plan to cut approximately 11% of its workforce in response to increasing competition in the weight-loss drug market [1][2]. Group 1: Restructuring Details - The company plans to reduce around 9,000 positions, with over half of these cuts occurring in Denmark, aiming for annualized savings of about $1.25 billion by the end of 2026 [2][5]. - The restructuring will incur one-off net costs of approximately $1.25 billion, primarily in the third quarter of this year [5]. - This move marks a reversal from a previous hiring spree that increased the workforce by 75% over the last five years [4]. Group 2: Strategic Focus - The savings from the workforce reduction will be redirected towards growth opportunities in diabetes and obesity therapies, including commercial execution initiatives and R&D programs [3][4]. - The CEO emphasized the need for the company to evolve in a competitive and consumer-driven market, focusing on a performance-based culture [3]. Group 3: Market Reaction - Following the announcement of the restructuring plan, Novo Nordisk's shares saw a positive response, with Danish-listed stock rising approximately 3% and U.S. shares climbing around 1.7% in pre-market trading [6].